Recent MGTX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/15/2026 01:06:37 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/15/2026 01:00:27 AM
- MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/14/2026 08:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2026 12:30:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2026 12:06:12 PM
- MeiraGTx Reports First Quarter 2026 Financial and Operational Results • GlobeNewswire Inc. • 05/14/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/30/2026 12:16:30 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/30/2026 12:09:42 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/30/2026 12:04:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/24/2026 12:35:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 01:01:19 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/22/2026 12:59:40 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 04/16/2026 09:25:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/16/2026 09:25:36 PM
- MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares • GlobeNewswire Inc. • 04/16/2026 11:47:22 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/16/2026 11:16:21 AM
- MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP) • GlobeNewswire Inc. • 04/16/2026 11:10:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/16/2026 11:09:05 AM
- MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia • GlobeNewswire Inc. • 04/16/2026 11:00:00 AM
- MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/08/2026 12:57:40 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/07/2026 08:17:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/30/2026 12:13:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/26/2026 12:25:09 PM
